BIOMAT Database Logo BIOMAT Database Logo

Acute antibody-mediated rejection in living ABO-incompatible kidney transplantation: long-term impact and risk factors. 2009

D Toki, and H Ishida, and K Setoguchi, and T Shimizu, and K Omoto, and H Shirakawa, and S Iida, and S Horita, and M Furusawa, and T Ishizuka, and Y Yamaguchi, and K Tanabe
Department of Urology, Tokyo Women's Medical University, Tokyo, Japan. tokidsk@gmail.com

The impact of acute antibody-mediated rejection (AAMR) on the long-term outcome on ABO-incompatible (ABOI) kidney transplantation is not well understood. We retrospectively analyzed the long-term impact of AAMR and risk factors for AAMR in 57 consecutive recipients performed between 1999 and 2004. Nineteen patients (33%) who developed AAMR within 3 months posttransplantation constituted of the AMR group. The graft survival rate was significantly lower in the AMR group (AMR vs. non-AMR, respectively; 5 years: 84% vs. 95%; 8 years: 45% vs. 95%; p = 0.009). The prevalence of transplant glomerulopathy at 1 year posttransplantation was significantly higher in the AMR group (AMR 64% vs. non-AMR 3%, p < 0.001). Multivariate analysis demonstrated that anti-blood group IgG antibody titers of 1:32 at the time of transplantation (OR, 9.52; p = 0.041) and donor-specific anti-HLA antibodies (DSHA) detected by Luminex single bead method (OR, 5.68; p = 0.015) were independent risk factors for AAMR regardless of baseline anti-blood group IgG antibody titers. Our results indicate that AAMR has a heavy impact on the long-term outcome and preoperative DSHA appears to have a more significant association with poor graft outcomes than anti-blood group antibodies, even in ABOI kidney transplantation.

UI MeSH Term Description Entries
D008297 Male Males
D001787 Blood Group Incompatibility An antigenic mismatch between donor and recipient blood. Antibodies present in the recipient's serum may be directed against antigens in the donor product. Such a mismatch may result in a transfusion reaction in which, for example, donor blood is hemolyzed. (From Saunders Dictionary & Encyclopedia of Laboratory Medicine and Technology, 1984). ABO Compatibility,ABO Incompatibility,Blood Group ABO Incompatibility,Blood Type Incompatibility,Rh Compatibility,Rh Incompatibility,ABO Compatibilities,ABO Incompatibilities,Blood Group Incompatibilities,Blood Type Incompatibilities,Compatibility, ABO,Compatibility, Rh,Incompatibilities, Blood Group,Incompatibility, ABO,Incompatibility, Blood Group,Incompatibility, Blood Type,Incompatibility, Rh,Rh Compatibilities,Rh Incompatibilities
D003401 Creatine An amino acid that occurs in vertebrate tissues and in urine. In muscle tissue, creatine generally occurs as phosphocreatine. Creatine is excreted as CREATININE in the urine.
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000017 ABO Blood-Group System The major human blood type system which depends on the presence or absence of two antigens A and B. Type O occurs when neither A nor B is present and AB when both are present. A and B are genetic factors that determine the presence of enzymes for the synthesis of certain glycoproteins mainly in the red cell membrane. ABH Blood Group,ABO Blood Group,ABO Factors,Blood Group H Type 1 Antigen,H Blood Group,H Blood Group System,ABO Blood Group System,Blood Group, ABH,Blood Group, ABO,Blood Group, H,Blood-Group System, ABO,Factors, ABO,System, ABO Blood-Group
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000906 Antibodies Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).

Related Publications

D Toki, and H Ishida, and K Setoguchi, and T Shimizu, and K Omoto, and H Shirakawa, and S Iida, and S Horita, and M Furusawa, and T Ishizuka, and Y Yamaguchi, and K Tanabe
Acute antibody-mediated rejection limited to medullary lesions in following ABO-incompatible living donor kidney transplantation.
March 2021, Korean journal of transplantation,
D Toki, and H Ishida, and K Setoguchi, and T Shimizu, and K Omoto, and H Shirakawa, and S Iida, and S Horita, and M Furusawa, and T Ishizuka, and Y Yamaguchi, and K Tanabe
ABO antibody titer and risk of antibody-mediated rejection in ABO-incompatible renal transplantation.
May 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,
D Toki, and H Ishida, and K Setoguchi, and T Shimizu, and K Omoto, and H Shirakawa, and S Iida, and S Horita, and M Furusawa, and T Ishizuka, and Y Yamaguchi, and K Tanabe
Association between response to rituximab and antibody-mediated rejection in ABO-incompatible living kidney transplantation.
December 2019, International journal of urology : official journal of the Japanese Urological Association,
D Toki, and H Ishida, and K Setoguchi, and T Shimizu, and K Omoto, and H Shirakawa, and S Iida, and S Horita, and M Furusawa, and T Ishizuka, and Y Yamaguchi, and K Tanabe
Histologic findings of antibody-mediated rejection in ABO blood-group-incompatible living-donor kidney transplantation.
January 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,
D Toki, and H Ishida, and K Setoguchi, and T Shimizu, and K Omoto, and H Shirakawa, and S Iida, and S Horita, and M Furusawa, and T Ishizuka, and Y Yamaguchi, and K Tanabe
Acute Antibody-mediated Rejection Coexisting With T Cell-mediated Rejection in Pediatric ABO-incompatible Transplantation.
September 2022, Transplantation direct,
D Toki, and H Ishida, and K Setoguchi, and T Shimizu, and K Omoto, and H Shirakawa, and S Iida, and S Horita, and M Furusawa, and T Ishizuka, and Y Yamaguchi, and K Tanabe
Daratumumab for Treatment of Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation.
January 2019, Case reports in nephrology and dialysis,
D Toki, and H Ishida, and K Setoguchi, and T Shimizu, and K Omoto, and H Shirakawa, and S Iida, and S Horita, and M Furusawa, and T Ishizuka, and Y Yamaguchi, and K Tanabe
Acute antibody-mediated rejection after ABO-incompatible kidney transplantation treated successfully with antigen-specific immunoadsorption.
January 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
D Toki, and H Ishida, and K Setoguchi, and T Shimizu, and K Omoto, and H Shirakawa, and S Iida, and S Horita, and M Furusawa, and T Ishizuka, and Y Yamaguchi, and K Tanabe
Postoperative rebound of antiblood type antibodies and antibody-mediated rejection after ABO-incompatible living-related kidney transplantation.
March 2015, Transplant international : official journal of the European Society for Organ Transplantation,
D Toki, and H Ishida, and K Setoguchi, and T Shimizu, and K Omoto, and H Shirakawa, and S Iida, and S Horita, and M Furusawa, and T Ishizuka, and Y Yamaguchi, and K Tanabe
Plasma cell-rich rejection accompanied by acute antibody-mediated rejection in a patient with ABO-incompatible kidney transplantation.
June 2014, Nephrology (Carlton, Vic.),
D Toki, and H Ishida, and K Setoguchi, and T Shimizu, and K Omoto, and H Shirakawa, and S Iida, and S Horita, and M Furusawa, and T Ishizuka, and Y Yamaguchi, and K Tanabe
ABO-incompatible kidney transplantation: long-term outcomes.
January 2013, Clinical transplants,
Copied contents to your clipboard!